Oddo BHF Asset Management Sas Takes $3.30 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Oddo BHF Asset Management Sas purchased a new stake in shares of Twist Bioscience Co. (NASDAQ:TWSTFree Report) during the third quarter, HoldingsChannel.com reports. The fund purchased 73,091 shares of the company’s stock, valued at approximately $3,302,000.

A number of other institutional investors have also recently made changes to their positions in TWST. Thrivent Financial for Lutherans purchased a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $43,992,000. Point72 Asset Management L.P. boosted its holdings in shares of Twist Bioscience by 1,021.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock valued at $33,168,000 after acquiring an additional 613,057 shares during the last quarter. Fred Alger Management LLC boosted its holdings in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock valued at $32,272,000 after acquiring an additional 575,080 shares during the last quarter. State Street Corp boosted its holdings in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after acquiring an additional 526,028 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in shares of Twist Bioscience by 188.5% in the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after buying an additional 521,272 shares during the last quarter.

Insider Activity

In other news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares in the company, valued at $3,068,728.57. This trade represents a 1.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the sale, the chief executive officer now owns 589,552 shares in the company, valued at approximately $26,294,019.20. The trade was a 2.37 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 101,787 shares of company stock worth $4,584,508 over the last quarter. Insiders own 3.92% of the company’s stock.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $47.90 on Friday. The stock has a market cap of $2.84 billion, a P/E ratio of -13.16 and a beta of 1.82. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The firm’s 50 day moving average price is $44.85 and its 200-day moving average price is $46.60.

Analysts Set New Price Targets

A number of research firms recently issued reports on TWST. Barclays dropped their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, November 19th. Scotiabank raised their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 19th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.90.

View Our Latest Report on TWST

Twist Bioscience Company Profile

(Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Further Reading

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWSTFree Report).

Institutional Ownership by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.